ASTX030
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
MDS Centers of Excellence
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Sort by
Center of Excellence
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack Meridian Health
Hackensack, NJ
- Accepting patients
Center of Excellence
Roswell Park Cancer Institute
Buffalo, NY
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
Weill Cornell
New York, NY
- Accepting patients
Oregon Oncology Specialists
Salem, OR
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
- Accepting patients
- Accepting patients
Center of Excellence
Smilow Cancer Hospital at Yale New Haven
New Haven, CT
- Accepting patients
496 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.